Metabolic profiling in personalized medicine: Bridging the gap between knowledge and clinical practice in type 2 diabetes

Personalized Medicine

Volumn 8, Issue 4, 2011, Pages 445-456

  Zolotov, Sagit ^a   Ben Yosef, Dafna ^a   Rishe, Naphtali D ^b   Yesha, Yelena ^c   Karnieli, Eddy ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

biomarkers; decision support system; diabetes; metabolic profiling; personalized medicine; prediction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; MEGLITINIDE; METFORMIN; SEX HORMONE BINDING GLOBULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

BIOINFORMATICS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG ELIMINATION; DRUG METABOLISM; FAMILY HISTORY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; LIFESTYLE MODIFICATION; MASS SPECTROMETRY; MEDICAL PRACTICE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79960948909     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.36     Document Type: Review

References (66)

1. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care 32, 2225-2229 (2009).
2. Update of ADA's major position statement, 'standards of medical care in diabetes'. Introduction. Diabetes Care 34(Suppl. 1), S1-S2 (2011).
3. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167, 1145-1151 (2007). (Pubitemid 46924742)
4. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 21, 1138-1145 (1998). (Pubitemid 28368522)
5. Lutgers HL, Gerrits EG, Sluiter WJ et al. Life expectancy in a large cohort of Type 2 diabetes patients treated in primary care (ZODIAC-10).PLoS ONE 4(8), e6817 (2009).
6. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002). (Pubitemid 34437694)
7. Tai ES, Goh SY, Lee JJ et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27, 1728-1734 (2004). (Pubitemid 38857451)
8. Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 27, 592-601 (2004).
9. Tirosh A, Shai I, Tekes-Manova D, Israeli E et al. Normal fasting plasma glucose levels and Type 2 diabetes in young men. N. Engl. J. Med. 353, 1454-1462 (2005). (Pubitemid 41400919)
10. Tirosh A, Shai I, Bitzur R et al. Changes in triglyceride levels over time and risk of Type 2 diabetes in young men. Diabetes Care 31, 2032-2037 (2008).
11. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J. Clin. Endocrinol. Metab. 79, 265-271 (1994). (Pubitemid 24221194)
12. Golden SH, Dobs AS, Vaidya D et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J. Clin. Endocrinol. Metab. 92, 1289-1295 (2007). (Pubitemid 46556400)
13. Ding EL, Song Y, Manson JE et al. Sex hormone-binding globulin and risk of Type 2 diabetes in women and men. N. Engl. J. Med. 361, 1152-1163 (2009).
14. Albertini JP, Valensi P, Lormeau B et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care 21, 1008-1013 (1998). (Pubitemid 28488797)
15. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus. JAMA 291, 1978-1986 (2004). (Pubitemid 38544279)
16. Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies novel risk loci for Type 2 diabetes. Nature 445, 881-885 (2007).
17. Meigs JB, Shrader P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of Type 2 diabetes. N. Engl. J. Med. 359, 2208-2219 (2008).
18. Lyssenko V, Jonsson A, Almgren P et al. Clinical risk factors, DNA variants, and the development of Type 2 diabetes. N. Engl. J. Med. 359, 2220-2232 (2008).
19. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict Type 2 diabetes risk. Diabetes Care 26, 725-731 (2003). (Pubitemid 36929335)
20. Grant RW, Moore AF, Florez JC. Genetic architecture of Type 2 diabetes: recent progress and clinical implications. Diabetes Care 32, 1107-1114 (2009).
21. Wang J, Stancakova A, Kuusisto J, Laakso M. Identification of undiagnosed Type 2 diabetic individuals by the Finnish diabetes risk score and biochemical and genetic markers: a population-based study of 7232 Finnish men. J. Clin. Endocrinol. Metab. 95, 3858-3862 (2010).
22. De Miguel-Yanes J, Shrader P, Pencina M et al. Genetic risk reclassification for Type 2 diabetes by age below or above 50 years using 40 Type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 34, 121-125 (2011).
23. Lucio M, Fekete A, Weigert C et al. Insulin sensitivity is reflected by characteristic metabolic fingerprints-a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS ONE 5, e13317 (2010).
24. Feero WG, Guttmacher AE, McCarthy MI. Genomics, Type 2 diabetes, and obesity. N. Engl. J. Med. 363, 2339-2350 (2010).
25. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J. Med. 77, 511-523 (2010).
26. Cheng AY, Leiter LA. Cardiovascular risk and glycemic control. CMAJ 180, 907-908 (2009).
27. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
28. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 164, 2090-2095 (2004). (Pubitemid 39410797)
29. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005). (Pubitemid 41817713)
30. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
31. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486-494 (2003). (Pubitemid 37430502)
32. Hernandez C, Francisco G, Chacon P, Simo R. Lipoprotein(a) as a risk factor for cardiovascular mortality in Type 2 diabetic patients: a 10-year follow-up study. Diabetes Care 28, 931-933 (2005). (Pubitemid 40434500)
33. Kollerits B, Auinger M, Reisig V et al. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with Type 1 diabetes. Diabetes Care 29, 1661-1663 (2006). (Pubitemid 44127599)
34. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102, 1082-1085 (2000).
35. Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with Type 2 diabetes mellitus. Mayo Clin. Proc. 76, 707-712 (2001).
36. Sunayama S, Daida H, Mokuno H et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Circulation 94, 1263-1268 (1996). (Pubitemid 26307251)
37. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310, 356-360 (1984). (Pubitemid 14179541)
38. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int. Suppl. 92, S2-S6 (2004).
39. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 41, 836-839 (1992).
40. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk factor intervention study group. Am. J. Cardiol. 80, 164-169 (1997). (Pubitemid 27329215)
41. Mollsten A, Lajer M, Jorsal A, Tarnow L. The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in Type 1 diabetes. Mol. Genet. Metab. 97, 80-84 (2009).
42. Qi L, Doria A, Manson JE et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with Type 2 diabetes. Diabetes 55, 1512-1516 (2006). (Pubitemid 44195395)
43. Distefano JK, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 3, 2610-2646 (2010).
44. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetologia 52, 17-30 (2009).
45. Standards of medical care in diabetes - 2010. Diabetes Care 33(Suppl. 1), S11-S61 (2010).
46. Pearson ER. Pharmacogenetics in diabetes. Curr. Diab. Rep. 9, 172-181 (2009).
47. Hutson S. Researchers sound alarm on 'silent' drug interactions. Nat. Med. 17, 6 (2011).
48. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug. Metab. Dispos. 35, 1956-1962 (2007). (Pubitemid 47481592)
49. Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20, 379-386 (2005).
50. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510-515 (2002). (Pubitemid 34787213)
51. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007). (Pubitemid 46718430)
52. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001). (Pubitemid 32995375)
53. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57, 306-314 (2008).
54. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (2005). (Pubitemid 41780780)
55. Jablonski KA, McAteer JB, de Bakker PI et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672-2681 (2010).
56. Marchetti P, Scharp DW, Giannarelli R et al. Metformin potentiates glucose-stimulated insulin secretion. Diabetes Care 19, 781-782 (1996). (Pubitemid 26249738)
57. Marchetti P, Lupi R, Del Guerra S et al. Goals of treatment for Type 2 diabetes: b-cell preservation for glycemic control. Diabetes Care 32(Suppl. 2), S178-S183 (2009).
58. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-a in mice. Diabetologia 54(2), 339-349 (2011).
59. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362, 1275-1281 (2003). (Pubitemid 37324255)
60. Blum S, Vardi M, Brown JB et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11, 675-684 (2010).
61. Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care 31, 1939-1944 (2008).
62. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 342, 154-160 (2000). (Pubitemid 30051646)
63. Bain JR, Stevens RD, Wenner BR et al. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58, 2429-2443 (2009).
64. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid - a facet of hyperinsulinaemia. Diabetologia 30, 713-718 (1987). (Pubitemid 17155777)
65. Huffman KM, Shah SH, Stevens RD et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32, 1678-1683 (2009).
66. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).